Analysts’ Viewpoint on Ultra-Large Volume Wearable Injectors Market Scenario
The global ultra-large volume wearable injectors market is growing at a rapid pace, as there are a large number of patients who depend on large-volume wearable injectors to receive continuous drug delivery into their body. The surge in the demand for more advanced treatment options for chronic diseases, such as diabetes, boosts the ultra-large volume wearable injectors market. Additionally, there has been an increase in focus by key players on the launch of new products in the market; for instance, West Pharmaceutical announced the new extensions of its SmartDose drug delivery platform, including several new wearable injectors that enable patients to inject 10 mL volume in easy-to-use, wearable formats.
Ultra-large volume wearable injectors are wearable injector systems that are able to store large volumes of drugs and designed to deliver the drug subcutaneously over an extended period of time. These wearable drug delivery devices are majorly used in the treatment of chronic diseases such as cancer, diabetes, and autoimmune disorders. Wearable injectors offer a solution to the challenge of delivering sub-cutaneous injections of increasing dosing volumes and viscosities in non-clinical settings. West Pharmaceutical Company’s SmartDose 10 On-Body Delivery System (OBDS) consists of a battery-powered, wearable on-body injector with a separate, pre-fillable, polymer-based cartridge that is filled with the drug product.
The ability of ultra-large volume wearable injectors to accommodate new formulations with higher volume and viscosity improves patient experience, and potentially increases adherence to therapies.
Chronic diseases, such as diabetes, cardiovascular disorders, autoimmune disorders, and various types of cancer, are the leading causes of death and disability worldwide. According to the Centers for Disease Control and Prevention (CDC) in 2019, nearly six in 10 individuals suffer from, at least, one chronic disease in the U.S.
Cardiovascular diseases (CVDs) are a significant cause of mortality, globally, owing to the hectic lifestyle. As per the World Health Organization (WHO), CVDs are the number one cause of death, globally, taking an estimated 17.9 million lives each year. According to the International Diabetes Federation (IDF), around 537 million adults (aged 20 -79) are living with diabetes globally. Furthermore, it has been stated that the number of diabetic patients would increase to 643 million by 2030 and 783 million by the year 2045.
In diabetes patients, the exogenous insulin is usually administered through a subcutaneous route of administration for diabetes management. The wearable injector is an ideal drug delivery method for painless and accurate dosage of insulin.
Self-administration devices are being increasingly used, as most of the people prefer treating themselves at the convenience of their home or own space. After the onset of the COVID-19 pandemic, most of the people preferred home treatment, as they did not want to contract the infection. Therefore, COVID-19 prompted the use of self-administration devices among people who required continuous drug delivery or treatment. Therefore, the wearable injectors market is estimated to grow due to the dependency of individuals on self-administration devices.
The diabetes segment accounted for a dominant share of the global market in 2021. The segment is anticipated to expand at a high CAGR from 2022 to 2031. The growth of the diabetes segment is due to a rise in the number of diabetic patients globally. Moreover, diabetic patients who are insulin dependent prefer wearing an injector on their body rather than using a syringe to inject themselves. Therefore, these factors are estimated to boost the ultra-large volume wearable injectors market.
For instance, as per the World Health Organization (WHO), around 422 million people have diabetes, worldwide; most of those people are living in low and middle income countries, and 1.5 million deaths are directly attributed to diabetes each year. Number of cases and the prevalence of diabetes have been rising at a steady pace for the past few decades.
In terms of distribution channel, the global market has been divided into retail pharmacies & drug stores, e-commerce, and others. The high market share held by the retail pharmacies & drug stores segment is due to increased number of patients that are preferring ultra-large volume wearable injectors for various drug deliveries. Retail pharmacies and drug stores sell different wearable injectors and hence, this has become convenient for purchasing and usage.
North America dominated the global ultra large volume wearable injectors market. The growth of the market in the region can be attributed to an increase in prevalence of chronic diseases, such as cancer, diabetes, oncology, cardiovascular diseases; development of new products, and presence of key market players in the region. Furthermore, technological advancements in the treatment of diseases are expected to be a key driver for the ultra-large volume wearable injectors market in the U.S. and Canada.
Asia Pacific is the expected to be fastest growing market for ultra-large volume wearable injectors, owing to increase in geriatric population, rise in prevalence of chronic diseases, supportive government initiatives, and research in the field of wearable medical devices. Additionally, investments by international market players fuel the growth of the market.
Amgen, Inc., Medtronic, BD, Insulet Corporation, Gerresheimer AG (Sensile Medical), West Pharmaceutical Services, Inc., Ypsomed AG, Tandem Diabetes Care, Inc., Cequr SA, Debiotech S.A, Elcam Medical, and VALERITAS, INC. are among the key companies operating in the ultra-large volume wearable injectors market. This report profiles key players in the global ultra-large volume wearable injectors market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global ultra-large volume wearable injectors market is highly fragmented, with the presence of numerous global as well as regional players.
Leading players in the ultra-large volume wearable injectors market are engaged in regulatory approvals, launch of technologically advanced products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the global ultra-large volume wearable injectors market. Companies have increased their research and development activities for ultra-large volume wearable injectors.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 2.8 Bn |
|
Market Forecast Value in 2031 |
US$ 6.6 Bn |
|
Growth Rate (CAGR) |
9.1% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global ultra-large volume wearable injectors market was valued at US$ 2.8 Bn in 2021.
The global ultra-large volume wearable injectors market is likely to surpass US$ 6.6 Bn by 2031.
The global ultra-large volume wearable injectors market is anticipated to record a CAGR of 7.8% from 2017 to 2021.
The global ultra-large volume wearable injectors market is anticipated to record a CAGR of 9.1% from 2022 to 2031.
Increasing prevalence of chronic diseases positively impacts the global market.
The diabetes segment held more than 60% share of the global ultra-large volume wearable injectors market in 2021.
North America is expected to hold a key share of the global market during the forecast period.
Prominent players in the global ultra-large volume wearable injectors market include Becton, Dickinson and Company, Bühler Motor GmbH, West Pharmaceutical Services, Inc., Ypsomed AG, Medtronic, Sonceboz, Enable Injections, Subcuject Aps, Nemera, Eitan Medical, Weibel CDS AG, and Gerresheimer AG.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Ultra-large Volume Wearable Injectors Market
4. Market Overview
4.1. Introduction
4.1.1. Indication Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ultra-large Volume Wearable Injectors Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Industry Developments
5.3. Ultra-large Volume Wearable Injectors Overview
5.4. COVID-19 Pandemics Impact on Industry
6. Global Ultra-large Volume Wearable Injectors Market Analysis and Forecast, by Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Indication, 2017–2031
6.3.1. Diabetes
6.3.2. Autoimmune Diseases
6.3.3. Oncology
6.3.4. Others
6.4. Market Attractiveness, by Indication
7. Global Ultra-large Volume Wearable Injectors Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Retail Pharmacies & Drug stores
7.3.2. E-commerce
7.3.3. Others
7.4. Market Attractiveness, by Distribution Channel
8. Global Ultra-large Volume Wearable Injectors Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Ultra-large Volume Wearable Injectors Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Indication, 2017–2031
9.2.1. Diabetes
9.2.2. Autoimmune Diseases
9.2.3. Oncology
9.2.4. Others
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Retail Pharmacies & Drug stores
9.3.2. E-commerce
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Indication
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Ultra-large Volume Wearable Injectors Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Indication, 2017–2031
10.2.1. Diabetes
10.2.2. Autoimmune Diseases
10.2.3. Oncology
10.2.4. Others
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Retail Pharmacies & Drug stores
10.3.2. E-commerce
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Indication
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Ultra-large Volume Wearable Injectors Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Indication, 2017–2031
11.2.1. Diabetes
11.2.2. Autoimmune Diseases
11.2.3. Oncology
11.2.4. Others
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Retail Pharmacies & Drug stores
11.3.2. E-commerce
11.3.3. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Indication
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Ultra-large Volume Wearable Injectors Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Indication, 2017–2031
12.2.1. Diabetes
12.2.2. Autoimmune Diseases
12.2.3. Oncology
12.2.4. Others
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Retail Pharmacies & Drug stores
12.3.2. E-commerce
12.3.3. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Indication
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Ultra-large Volume Wearable Injectors Market Analysis and Forecast
. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Indication, 2017–2031
13.2.1. Diabetes
13.2.2. Autoimmune Diseases
13.2.3. Oncology
13.2.4. Others
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Retail Pharmacies & Drug stores
13.3.2. E-commerce
13.3.3. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Indication
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Company Profiles
14.2.1. Becton, Dickinson and Company
14.2.1.1. Company Overview
14.2.1.2. Financial Overview
14.2.1.3. Product Portfolio
14.2.1.4. SWOT Analysis
14.2.1.5. Strategic Overview
14.2.2. Bühler Motor GmbH
14.2.2.1. Company Overview
14.2.2.2. Financial Overview
14.2.2.3. Product Portfolio
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. West Pharmaceutical Services, Inc.
14.2.3.1. Company Overview
14.2.3.2. Financial Overview
14.2.3.3. Product Portfolio
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Ypsomed AG
14.2.4.1. Company Overview
14.2.4.2. Financial Overview
14.2.4.3. Product Portfolio
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Medtronic
14.2.5.1. Company Overview
14.2.5.2. Financial Overview
14.2.5.3. Product Portfolio
14.2.5.4. SWOT Analysis
14.2.5.5. Strategic Overview
14.2.6. Sonceboz
14.2.6.1. Company Overview
14.2.6.2. Financial Overview
14.2.6.3. Product Portfolio
14.2.6.4. SWOT Analysis
14.2.6.5. Strategic Overview
14.2.7. Enable Injections
14.2.7.1. Company Overview
14.2.7.2. Financial Overview
14.2.7.3. Product Portfolio
14.2.7.4. SWOT Analysis
14.2.7.5. Strategic Overview
14.2.8. Subcuject Aps
14.2.8.1. Company Overview
14.2.8.2. Financial Overview
14.2.8.3. Product Portfolio
14.2.8.4. SWOT Analysis
14.2.8.5. Strategic Overview
14.2.9. Nemera
14.2.9.1. Company Overview
14.2.9.2. Financial Overview
14.2.9.3. Product Portfolio
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Eitan Medical
14.2.10.1. Company Overview
14.2.10.2. Financial Overview
14.2.10.3. Product Portfolio
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview
14.2.11. Weibel CDS AG
14.2.11.1. Company Overview
14.2.11.2. Financial Overview
14.2.11.3. Product Portfolio
14.2.11.4. SWOT Analysis
14.2.11.5. Strategic Overview
14.2.12. Gerresheimer AG
14.2.12.1. Company Overview
14.2.12.2. Financial Overview
14.2.12.3. Product Portfolio
14.2.12.4. SWOT Analysis
14.2.12.5. Strategic Overview
List of Tables
Table 01: Global Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 02: Global Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Distribution Channel, 2017‒2031
Table 03: Global Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Region, 2017–2031
Table 04: North America Continence Care Market Value (US$ Bn) Forecast, by Country, 2017–2031
Table 05: North America Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 06: North America Ultra-large Volume Wearable Injectors Market (US$ Bn) Forecast, by Distribution Channel, 2017–2031
Table 07: Europe Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031
Table 08: Europe Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 09: Europe Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031
Table 10: Asia Pacific Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031
Table 11: Asia Pacific Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 12: Asia Pacific Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031
Table 13: Latin America Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031
Table 14: Latin America Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 15: Latin America Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031
Table 16: Middle East & Africa Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031
Table 17: Middle East & Africa Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Indication, 2017–2031
Table 18: Middle East & Africa Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, 2017–2031
Figure 02: Global Ultra-large Volume Wearable Injectors Market Value Share, by Indication, 2021
Figure 03: Global Ultra-large Volume Wearable Injectors Market Value Share, by Distribution Channel, 2021
Figure 04: Global Ultra-large Volume Wearable Injectors Market Value Share, by Region, 2021
Figure 05: Global Ultra-large Volume Wearable Injectors Market, by Indication, 2021 and 2031
Figure 06: Global Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Indication, 2021–2031
Figure 07: Global Ultra-large Volume Wearable Injectors Market (US$ Bn), by Diabetes, 2017–2031
Figure 08: Global Ultra-large Volume Wearable Injectors Market (US$ Bn), by Autoimmune Diseases, 2017–2031
Figure 09: Global Ultra-large Volume Wearable Injectors Market (US$ Bn), by Oncology, 2017–2031
Figure 10: Global Ultra-large Volume Wearable Injectors Market (US$ Bn), by Others, 2017–2031
Figure 11: Global Ultra-large Volume Wearable Injectors Market, by Distribution Channel, 2021 and 2031
Figure 12: Global Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 13: Global Ultra-large Volume Wearable Injectors Market (US$ Bn), by Retail Pharmacies & Drug stores, 2017–2031
Figure 14: Global Ultra-large Volume Wearable Injectors Market (US$ Bn), by E-commerce, 2017–2031
Figure 15: Global Ultra-large Volume Wearable Injectors Market (US$ Bn), by Others, 2017–2031
Figure 16: Global Ultra-large Volume Wearable Injectors Market Value Share Analysis, by Region, 2021 and 2031
Figure 17: Global Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Region, 2022–2031
Figure 18: North America Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, 2017–2031
Figure 19: North America Ultra-large Volume Wearable Injectors Market Value Share Analysis, by Country, 2021 and 2031
Figure 20: North America Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Country, 2022–2031
Figure 21: North America Ultra-large Volume Wearable Injectors Market, by Indication, 2020 and 2031
Figure 22: North America Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Indication, 2022–2031
Figure 23: North America Ultra-large Volume Wearable Injectors Market, by Indication, 2020 and 2031
Figure 24: North America Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Indication, 2021–2031
Figure 25: Europe Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, 2017–2031
Figure 26: Europe Ultra-large Volume Wearable Injectors Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
Figure 27: Europe Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 28: Europe Ultra-large Volume Wearable Injectors Market, by Indication, 2020 and 2031
Figure 29: Europe Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Indication, 2022–2031
Figure 30: Europe Ultra-large Volume Wearable Injectors Market, by Distribution Channel, 2021 and 2031
Figure 31: Europe Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 32: Asia Pacific Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, 2017–2031
Figure 33: Asia Pacific Ultra-large Volume Wearable Injectors Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
Figure 34: Asia Pacific Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 35: Asia Pacific Ultra-large Volume Wearable Injectors Market, by Indication, 2021 and 2031
Figure 36: Asia Pacific Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Indication, 2022–2031
Figure 37: Asia Pacific Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 38: Asia Pacific Ultra-large Volume Wearable Injectors Market, by Distribution Channel, 2021 and 2031
Figure 39: Latin America Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, 2017–2031
Figure 40: Latin America Ultra-large Volume Wearable Injectors Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
Figure 41: Latin America Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 42: Latin America Ultra-large Volume Wearable Injectors Market, by Indication, 2021 and 2031
Figure 43: Latin America Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Indication, 2022–2031
Figure 44: Latin America Ultra-large Volume Wearable Injectors Market, by Distribution Channel, 2021 and 2031
Figure 45: Latin America Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 46: Middle East & Africa Ultra-large Volume Wearable Injectors Market Value (US$ Bn) Forecast, 2017–2031
Figure 47: Middle East & Africa Ultra-large Volume Wearable Injectors Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
Figure 48: Middle East & Africa Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 49: Middle East & Africa Ultra-large Volume Wearable Injectors Market, by Indication, 2021 and 2031
Figure 50: Middle East & Africa Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Indication, 2022–2031
Figure 51: Middle East & Africa Ultra-large Volume Wearable Injectors Market, by Distribution Channel, 2021 and 2031
Figure 52: Middle East & Africa Ultra-large Volume Wearable Injectors Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Ultra-large Volume Wearable Injectors Market
